Toll Free: 1-888-928-9744

Mycobacterium tuberculosis Protein Ag85A - Pipeline Review, H2 2016

Published: Aug, 2016 | Pages: 48 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Mycobacterium tuberculosis Protein Ag85A - Pipeline Review, H2 2016

Summary

Global Markets Direct's, 'Mycobacterium tuberculosis Protein Ag85A - Pipeline Review, H2 2016', provides in depth analysis on Mycobacterium tuberculosis Protein Ag85A targeted pipeline therapeutics. 

The report provides comprehensive information on the Mycobacterium tuberculosis Protein Ag85A, targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Mycobacterium tuberculosis Protein Ag85A targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Mycobacterium tuberculosis Protein Ag85A
- The report reviews Mycobacterium tuberculosis Protein Ag85A targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in Mycobacterium tuberculosis Protein Ag85A targeted therapeutics and enlists all their major and minor projects 
- The report assesses Mycobacterium tuberculosis Protein Ag85A targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news and deals related to Mycobacterium tuberculosis Protein Ag85A targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand the targeted therapy areas and indications for Mycobacterium tuberculosis Protein Ag85A
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Mycobacterium tuberculosis Protein Ag85A development landscape 
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
 Table of Contents
Table of Contents 2 List of Tables 4 List of Figures 4 Introduction 5 Global Markets Direct Report Coverage 5 Mycobacterium tuberculosis Protein Ag85A Overview 6 Therapeutics Development 7 Mycobacterium tuberculosis Protein Ag85A - Products under Development by Stage of Development 7 Mycobacterium tuberculosis Protein Ag85A - Products under Development by Therapy Area 8 Mycobacterium tuberculosis Protein Ag85A - Products under Development by Indication 9 Mycobacterium tuberculosis Protein Ag85A - Pipeline Products Glance 10 Early Stage Products 10 Mycobacterium tuberculosis Protein Ag85A - Products under Development by Companies 11 Mycobacterium tuberculosis Protein Ag85A - Products under Development by Universities/Institutes 13 Mycobacterium tuberculosis Protein Ag85A - Therapeutics Assessment 15 Assessment by Monotherapy/Combination Products 15 Assessment by Route of Administration 16 Assessment by Molecule Type 18 Mycobacterium tuberculosis Protein Ag85A - Companies Involved in Therapeutics Development 20 Imaxio SA 20 Mycobacterium tuberculosis Protein Ag85A - Drug Profiles 21 HG-85A - Drug Profile 21 Product Description 21 Mechanism Of Action 21 R&D Progress 21 HG-85A/B - Drug Profile 22 Product Description 22 Mechanism Of Action 22 R&D Progress 22 HG856-A - Drug Profile 23 Product Description 23 Mechanism Of Action 23 R&D Progress 23 HG856-BCG - Drug Profile 24 Product Description 24 Mechanism Of Action 24 R&D Progress 24 HG856-SeV - Drug Profile 25 Product Description 25 Mechanism Of Action 25 R&D Progress 25 IMX-313-TB - Drug Profile 26 Product Description 26 Mechanism Of Action 26 R&D Progress 26 MVA-85A - Drug Profile 27 Product Description 27 Mechanism Of Action 27 R&D Progress 27 TB/FLU-04L - Drug Profile 31 Product Description 31 Mechanism Of Action 31 R&D Progress 31 tuberculosis vaccine - Drug Profile 32 Product Description 32 Mechanism Of Action 32 R&D Progress 32 tuberculosis vaccine - Drug Profile 33 Product Description 33 Mechanism Of Action 33 R&D Progress 33 tuberculosis vaccine 2 - Drug Profile 34 Product Description 34 Mechanism Of Action 34 R&D Progress 34 Mycobacterium tuberculosis Protein Ag85A - Dormant Projects 35 Mycobacterium tuberculosis Protein Ag85A - Discontinued Products 36 Mycobacterium tuberculosis Protein Ag85A - Featured News & Press Releases 37 Mar 24, 2015: World-first TB vaccination trials enter next stage 37 Oct 02, 2013: New tuberculosis vaccine will help fight 'serious public health threat' 38 Sep 03, 2013: Imaxio announces the first human clinical trial using its pro-immunogenic technology IMX313, in tuberculosis 39 Feb 04, 2013: Emergent BioSolutions Reports Publication Of Data From Phase IIb Clinical Trial For Tuberculosis Vaccine Candidate MVA85A In Lancet 39 Dec 10, 2012: University Of Cape Town Begins New study On TB Vaccine For Newborns Of HIV-positive Mothers 41 Mar 22, 2012: Emergent BioSolutions Receives NIAID Grant To Support Tuberculosis Vaccine Candidate 41 Aug 11, 2011: Aeras And Oxford-Emergent Tuberculosis Consortium Announce Start Of Phase IIb Trial Of New Investigational Tuberculosis Vaccine In Senegal And South Africa 42 Apr 28, 2011: Oxford-Emergent Tuberculosis Consortium Vaccinates Last Infant In Phase IIb Clinical Trial 43 Feb 25, 2011: Delegates From European Parliament Express Support For Rapid Development Of Emergent's New TB Vaccine 44 Apr 22, 2009: New TB Vaccine Candidate Enters Phase IIb Proof-of-Concept Trial in South Africa 44 Jun 23, 2008: Emergent BioSolutions And University of Oxford Form Joint Venture To Develop Advanced Tuberculosis Vaccine 45 Oct 25, 2004: TB Vaccine MVA85A Succeeds In Safety Trials 46 Appendix 47 Methodology 47 Coverage 47 Secondary Research 47 Primary Research 47 Expert Panel Validation 47 Contact Us 47 Disclaimer 48
List of Tables
Number of Products under Development for, H2 2016 7 Number of Products under Development by Therapy Area, H2 2016 8 Number of Products under Development by Indication, H2 2016 9 Comparative Analysis by Early Stage Products, H2 2016 10 Number of Products under Development by Companies, H2 2016 11 Products under Development by Companies, H2 2016 12 Number of Products under Investigation by Universities/Institutes, H2 2016 13 Products under Investigation by Universities/Institutes, H2 2016 14 Assessment by Monotherapy/Combination Products, H2 2016 15 Number of Products by Stage and Route of Administration, H2 2016 17 Number of Products by Stage and Molecule Type, H2 2016 19 Pipeline by Imaxio SA, H2 2016 20 Dormant Projects, H2 2016 35 Discontinued Products, H2 2016 36



To request a free sample copy of this report, please complete the form below.

We never share your personal data. Privacy policy
Interested in this report? Get your FREE sample now! Get a Free Sample
Choose License Type
Single User - US $3500
Multi User - US $7000
Hexareeasearch Know

Did you know?

Research Assistance

Phone: 1-415-349-0054

Toll Free: 1-888-928-9744

Email: [email protected]

Why to buy from us

Custom research service

Speak to the report author to design an exclusive study to serve your research needs.

Information security

Your personal and confidential information is safe and secure.

verify